liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Clinical effectiveness of golimumab in Crohns disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
Orebro Univ, Sweden.
Orebro Univ, Sweden.
Danderyd Hosp, Sweden.
Helsingborg Hosp, Sweden.
Vise andre og tillknytning
2018 (engelsk)Inngår i: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 53, nr 10-11, s. 1257-1263Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: The effectiveness of golimumab in Crohns disease (CD) is largely unknown as it is not approved for the treatment of the disease. We aimed to identify the population of CD patients treated with golimumab in Sweden, to assess the effectiveness of golimumab (defined as the drug retention rate), and to identify predictors of drug discontinuation. Methods: Patients with CD who received at least one injection of golimumab were identified through the Swedish National Quality Registry for Inflammatory Bowel Disease, which includes prospectively collected clinical information. Cox regression models were used to identify predictors of golimumab discontinuation. Results: The study cohort involved 94 patients of whom the majority (96.8%) had previously discontinued at least one anti-tumour necrosis factor (anti-TNF) agent. The drug retention rate at 12 weeks was 85.1%. Predictors of golimumab discontinuation at 12 weeks were previous surgery (adjusted HR = 7.52, 95% CI: 1.12-50.36), concomitant corticosteroid use at baseline (adjusted HR = 5.70, 95% CI: 1.13-28.68) and female sex (adjusted HR = 6.59; 95% CI: 1.04-41.62). The median duration of follow-up was 89 (IQR: 32-158) weeks. The drug retention at the most recent follow-up was 35.1%. Predictors of golimumab discontinuation at the most recent follow-up were corticosteroid use at baseline (adjusted HR = 2.60, 95% CI: 1.17-5.79) and female sex (adjusted HR = 2.24; 95% CI: 1.19-4.23). Conclusion: Patients with CD treated with golimumab were a treatment-refractory group. Despite this, more than one-third of the patients appeared to have had clinical benefit after a median follow-up of more than 1.5 years.

sted, utgiver, år, opplag, sider
TAYLOR & FRANCIS LTD , 2018. Vol. 53, nr 10-11, s. 1257-1263
Emneord [en]
Golimumab; Crohns disease; biological treatment; SWIBREG; IBD
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-154736DOI: 10.1080/00365521.2018.1519597ISI: 000457980900016PubMedID: 30353751OAI: oai:DiVA.org:liu-154736DiVA, id: diva2:1292096
Tilgjengelig fra: 2019-02-27 Laget: 2019-02-27 Sist oppdatert: 2019-04-12

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Hjortswang, Henrik

Søk i DiVA

Av forfatter/redaktør
Hjortswang, Henrik
Av organisasjonen
I samme tidsskrift
Scandinavian Journal of Gastroenterology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 5 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf